How Will 10 Billion doses of COVID-19 Vaccine be Distributed Globally?

Curfews have been implemented in many places such as Paris, France; London, the United Kingdom upgraded the COVID-19 alert level from "medium" risk to "high" risk; Germany agreed to reduce the size of the gathering of people in COVID-19 hotspots; the chief infectious disease expert of the United States, Fu Dr. Qi warned that "we are in big trouble."

As the northern hemisphere gradually ushered in a cold winter, the epidemic hit again, and some countries and regions began a new round of blockade. To open up the economy and achieve recovery, vaccines are still a key key.

At present, there are nearly 200 new coronavirus vaccines under development worldwide. According to the latest information on the official website of the World Health Organization (WHO), as of October 15th, 42 COVID-19 models have entered the clinical trial phase, of which 10 models have entered the phase III clinical trial phase, and 4 models are from China.

The advent of an effective new crown vaccine seems to be predictable, and with the approaching mass production of vaccines, an unprecedentedly huge scale of transportation and distribution will bring challenges to the global logistics industry. A recent white paper jointly issued by DHL and McKinsey & Company shows that global demand for the COVID-19 vaccine is expected to exceed 10 billion doses after the advent of the vaccine. This requires about 200,000 pallet shipments, about 15 million cooling box shipments, and about 15,000. Flight transportation.

On October 8, China signed an agreement with the Global Alliance for Vaccines and Immunization to formally join the "COVAX". The Ministry of Foreign Affairs stated that the purpose of joining the "implementation plan" is to promote the fair distribution of vaccines with practical actions and ensure the provision of vaccines to developing countries.

The pharmaceutical industry itself has a more complex supply chain than other fields. In addition to pharmaceutical product manufacturers, raw material suppliers, logistics providers, distributors, and medical service providers (such as hospitals and clinics), its participants also include governments, Insurance institutions, drug purchasing organizations, etc. In addition, the specifications, varieties and batches of pharmaceutical products are numerous, and the requirements for production, circulation and storage are also different. As vaccines have more stringent requirements for circulation and storage, their supply chains are particularly complex.

But as far as the COVID-19 vaccine is concerned, some vaccine manufacturers in the late stages of clinical trials have revealed that they need more stringent temperature control. In order to ensure the effectiveness of vaccines during transportation and storage, this poses new logistics challenges for the existing medical supply chain that traditionally delivers vaccines at about 2°C to 8°C. "The key point of vaccine transportation is the cold chain, and observing the sensitivity of the vaccine to the cold chain may also be a way for us to determine the preferred vaccine.

Our company has COVID-19 Vaccine Container on sale, welcome to contact us.